RobertRisingerMD
Psychiatry • New Haven, CTChild & Adolescent Psychiatry, Neuropsychiatry, Psychopharmacology, Clinical Pharmacology
Physician
Dr. Risinger is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
BioXcel Therapeutics
555 Long Wharf Drive
New Haven, CT 06511
Summary
- Dr. Robert Risinger is a psychiatrist in New Haven, CT. He received his medical degree from University of Pittsburgh School of Medicine and has been in practice 29 years. He specializes in child & adolescent psychiatry, neuropsychiatry, psychopharmacology, and clinical pharmacology and is experienced in learning disorders and attention-deficit/hyperactivity disorder.
Education & Training
National Institutes of Health Clinical CenterResidency, Psychiatry, 1991 - 1994
Emory University School of MedicineResidency, Psychiatry, 1988 - 1991
University of Pittsburgh School of MedicineClass of 1988
Certifications & Licensure
WI State Medical License 1997 - 2025
Clinical Trials
- A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia Start of enrollment: 2015 Dec 01
- A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder Start of enrollment: 2015 Dec 01
- Sequential Therapy for the Treatment of Severe Bipolar Depression. Start of enrollment: 2018 Jan 15
- Join now to see all
Publications & Presentations
PubMed
- 219 citationsAmygdala response to both positively and negatively valenced stimuli.Hugh Garavan, J. Cara Pendergrass, Thomas J. Ross, Elliot A. Stein, Robert C. Risinger
Neuroreport. 2001-08-28 - 109 citationsRepeated N -Acetyl Cysteine Reduces Cocaine Seeking in Rodents and Craving in Cocaine-Dependent HumansShelley L. Amen, Linda B. Piacentine, Muhammad E Ahmad, Shi-Jiang Li, John R. Mantsch
Neuropsychopharmacology. 2011-03-01 - 6 citationsSublingual dexmedetomidine (BXCL501) reduces opioid withdrawal symptoms: findings from a multi-site, phase 1b/2, randomized, double-blind, placebo-controlled trial.Jermaine D Jones, Lavanya Rajachandran, Frank Yocca, Robert Risinger, Michael De Vivo
The American Journal of Drug and Alcohol Abuse. 2023-01-02
Press Mentions
BXCL501 Seen to Ease Alzheimer’s Agitation in Phase 3 TrialJuly 2nd, 2023- BioXcel Therapeutics Announces Positive Topline Results from TRANQUILITY II Phase 3 Trial of BXCL501 for Acute Treatment of Alzheimer’s Disease-Related AgitationJune 30th, 2023
- BioXcel Therapeutics Announces Promising Topline Results from Part 1 of Pivotal SERENITY III Trial of BXCL501 for at-Home Use in Acute Treatment of Agitation in Bipolar Disorders or SchizophreniaMay 25th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
